| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.6 |